fashion -WSS

fashion

author：focus 2025-09-30 16:50:00 - browse：5

Biogen, a biotech giant plagued by years of boardroom strife, said late Monday that the longtime and polarizing director Alex Denner would step down from its board, sending a signal to investors that the company’s fractious recent history might be coming to a close.

What Biogen didn’t disclose is that its nominee to replace Denner on the board, Susan Langer, is Denner’s live-in romantic partner and the mother of his child, born in November, according to court records obtained by STAT. Denner is in the middle of a protracted divorce from his wife of nearly 25 years, with whom he has two teenage sons — a bitter legal fight in which his extramarital relationship with Langer is a contentious issue, according to the records.

Biogen spokesperson Jack Cox said the company knew about the relationship between Denner and Langer. He also said that Denner recommended Langer to Biogen’s board — he said he incorrectly stated at first that Denner nominated her — but declined to comment on the company’s vetting process and whether it planned to disclose the relationship to shareholders before they vote on Langer’s candidacy later this month. Biogen also omitted mention of the relationship from Langer’s biography in a Securities and Exchange Commission filing Tuesday morning.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： What will Novo Nordisk's VC do with its influx of cash?

knowledge

WSS

STAT reporters are Pulitzer Prize finalists for investigative reporting

Free medical tuition alone isn't enough to close gaps in primary care

WuXi Biologics execs register to lobby as Congress comes for the company

New oral drug delivery patch is modeled after octopus tentacles

The Karikó problem: Lessons for funding basic research

European officials brace for rough respiratory virus season

knowledge

fashion

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Setback for rare diseases as Taysha Gene Therapies pulls back

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Duchenne breakthrough therapy leaves behind pioneering families

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

New air purifier tech could be key to improving indoor air quality

Hottest summer in 2,000 years puts focus on extreme heat, health

State Dept. review finds Biden bears some blame for Afghanistan failures

With Roe v Wade overturned, abortion providers work to adapt

hotspot

Medicare innovation center doesn’t save money, experts say

ALS treatment from Biogen, Ionis fails in study

Free medical tuition alone isn't enough to close gaps in primary care

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Fertility clinic egg and embryo storage is a disaster

focus

knowledge

focus

focus